Gsa Capital Partners LLP Pacira Bio Sciences, Inc. Transaction History

Gsa Capital Partners LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	SELL	$27.7 - $35.48 $56,231 - $72,024	-2,030 Reduced 8.2%	22,722 $663,000
Q4 2023 Feb 16, 2024	BUY	$26.32 - $34.31 $651,472 - $849,241	24,752 New	24,752 $835,000
Q1 2023 May 12, 2023	SELL	$35.53 - $43.38 $420,497 - $513,402	-11,835 Reduced 34.59%	22,384 $913,000
Q4 2022 Feb 13, 2023	BUY	$38.19 - $57.45 $1.31 Million - $1.97 Million	34,219 New	34,219 $1.32 Million
Q2 2020 Aug 11, 2020	SELL	$30.8 - $52.47 $673,750 - $1.15 Million	-21,875 Closed	0 $0
Q1 2020 May 12, 2020	BUY	$28.4 - $50.7 $621,250 - $1.11 Million	21,875 New	21,875 $733,000
Q4 2019 Feb 12, 2020	SELL	$36.31 - $46.83 $602,455 - $777,003	-16,592 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$35.66 - $44.99 $693,622 - $875,100	-19,451 Reduced 53.97%	16,592 $632,000
Q2 2019 Aug 06, 2019	BUY	$36.57 - $47.97 $1.32 Million - $1.73 Million	36,043 New	36,043 $1.57 Million
Q1 2019 May 15, 2019	SELL	$36.47 - $42.17 $269,878 - $312,058	-7,400 Closed	0 $0
Q4 2018 Feb 12, 2019	BUY	$41.31 - $52.16 $305,694 - $385,984	7,400 New	7,400 $318,000

260

49.8M

1.03M

139K

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $1.1B
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.